Investor Briefing with James McDonnell – 4 Feb 2026
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics Ltd (ASX: PTX) earlier this week received European authorisation to begin clinical trials...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
As the Wise Man sayeth, one should giveth a task to a busy person if...
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.